Publications by authors named "Krimo Bouabdallah"
Copanlisib, a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α and δ isoforms, previously demonstrated durable responses as monotherapy and improved progression-free survival (PFS) in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL). CHRONOS-4 was a phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of copanlisib in combination with standard immunochemotherapy in patients with relapsed iNHL. Patients (n = 524) were randomized (1:1) to copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine [R-B] or placebo plus R-B).
View Article and Find Full Text PDFArticle Synopsis
- Advances in lymphoma treatment have made assessing health-related quality of life (HRQoL) crucial for newly diagnosed patients, yet there's limited information on their HRQoL profiles at diagnosis.
- A study involving 3922 adults with various lymphoma types utilized three validated EORTC questionnaires to evaluate HRQoL at diagnosis, achieving high completion rates between 84% and 88%.
- Findings highlighted significant impairments in global health status across lymphoma subtypes, with factors like gender, performance status, and B symptoms affecting HRQoL, providing valuable insights for future research and clinical practices.
Article Synopsis
- Follicular helper T-cell lymphomas (TFHL) often have gene alterations affecting DNA methylation, and preliminary studies indicate that 5-azacitidine may be effective for patients with relapsed TFHL.
- This study compared the oral azacitidine treatment to typical therapies (like gemcitabine and bendamustine) in patients over 18 with relapsed or refractory TFHL across five European countries and Japan.
- The trial enrolled 86 patients, showing that those treated with azacitidine had a median progression-free survival of 5.6 months, significantly longer compared to 2.8 months for those receiving standard therapy.
The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT). Primary endpoint was time to treatment failure (TTF), secondary endpoints included response rates, progression free survival, overall survival, and safety.
View Article and Find Full Text PDFArticle Synopsis
- - Obinutuzumab (O) and rituximab (R) were compared in a long-term study (LyMa-101) for treating newly diagnosed mantle cell lymphoma (MCL) patients, focusing on outcomes like measurable residual disease (MRD), progression-free survival (PFS), and overall survival (OS).
- - Results showed that the O group had a higher rate of MRD negativity (83.1% vs 63.4%) and better long-term outcomes, with 5-year PFS at 82.8% and OS at 86.4%, compared to 66.6% and 71.4% for the R group, respectively.
- - The study concluded that using
In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.
View Article and Find Full Text PDFJCO The LYMA trial demonstrated the benefit of rituximab maintenance (RM) in first-line young patients with mantle-cell lymphoma. In this prolonged follow-up of 7.5 years (95% CI, 7.
View Article and Find Full Text PDFArticle Synopsis
- - The phase II trial assessed the effectiveness of the RiBVD treatment (rituximab, bendamustine, velcade, and dexamethasone) in patients over 65 with mantle cell lymphoma (MCL), which resulted in a median progression-free survival of 79 months and overall survival of 111 months.
- - TP53 mutation status and albumin levels were identified as significant prognostic factors, with TP53 mutations linked to a higher risk of shorter progression-free survival and overall survival in the analyzed patient population.
- - A scoring system combining TP53 mutation status and albumin levels allowed differentiation of patient outcomes, indicating varying survival rates based on the presence of these factors, thus enhancing prognostic assessments
Article Synopsis
- Real-world data (RWD) are crucial for enhancing clinical trial (CT) findings, but challenges like data quality persist; the REALYSA study, launched in 2018, focuses on newly diagnosed lymphoma patients in France.
- A proof-of-concept analysis of 645 patients with diffuse large B-cell lymphoma (DLBCL) found high data completeness (<4% missing) and revealed good survival rates, with a median follow-up of 9.9 months showing 1-year event-free survival of 77.9% and overall survival of 90.0%.
- The study also assessed how well REALYSA's patient outcomes matched those from recent phase 3 trials (POLARIX and SENIOR), demonstrating
Purpose: The combination of zanubrutinib plus obinutuzumab (ZO) was found to be well tolerated with an early signal of efficacy in a phase Ib study. ROSEWOOD is a phase II, randomized study that assessed the efficacy and safety of ZO versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Methods: Patients with R/R FL who had received ≥2 lines of therapy, including an anti-CD20 antibody and an alkylating agent, were randomly assigned 2:1 to receive ZO or obinutuzumab (O).
Article Synopsis
- * The final analysis presented a 41.5% overall response rate, with a median duration of response not reached, and 33% of patients remained progression-free after 4 years.
- * Most patients experienced mild to moderate treatment-related side effects, such as neutropenia and hypothyroidism, with only a small percentage facing severe adverse events, highlighting pembrolizumab's long-term safety and effectiveness.
Article Synopsis
- Rituximab treatment is more effective than the 'watch and wait' approach for low-tumor burden follicular lymphoma, improving progression-free survival (PFS) but maintenance therapy raised concerns about resource use and patient adherence.
- A study compared intravenous (IV) rituximab and subcutaneous (SC) rituximab adminstration in patients, demonstrating better 4-year PFS rates in the experimental SC group (58.1% vs 41.2%).
- While high exposure to rituximab during the first three months led to improved response rates, time to next treatment (TTNT) and overall survival (OS) showed no significant differences between the two approaches.
Purpose: This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of their baseline cell-free DNA (cfDNA) levels on their long-term survival.
Experimental Design: The GOELAMS 075 randomized clinical trial compared rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with high-dose R-chemotherapy plus autologous stem cell transplantation (R-HDT) for patients aged ≤60. An interim PET assessment was used to refer patients for salvage therapy.
Distinguishing between follicular lymphoma (FL) and nodal marginal zone lymphoma (NMZL) can be difficult when morphologic and phenotypic features are unusual and characteristic cytogenetic rearrangements are absent. We evaluated the diagnostic contribution of ancillary techniques-including fluorescence in situ hybridization (FISH)-detected 1p36 deletion; reverse-transcriptase, multiplex, ligation-dependent probe amplification (RT-MLPA); and next-generation sequencing (NGS)-for tumors that remain unclassified according to standard criteria. After review, 50 CD5-negative small B-cell lymphoid neoplasms without BCL2 and BCL6 FISH rearrangements were diagnosed as FLs (n = 27), NMZLs (n = 5), or unclassified (n = 18) based on the 2016 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues.
View Article and Find Full Text PDFPatients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination.
View Article and Find Full Text PDFArticle Synopsis
- ALK-negative anaplastic large cell lymphoma (ALCL) has subgroups based on gene rearrangements, specifically DUSP22-R and TP63-R, which show different survival rates, making the impact of DUSP22 results unclear.
- In a study involving 104 newly diagnosed ALCL patients, 45% showed DUSP22-R, indicating that tumors with this rearrangement had different characteristics, including more CD3 expression and more frequent bone involvement.
- The 5-year progression-free survival (PFS) was significantly higher in patients with DUSP22-R compared to those without, and while both performance status and DUSP22 status affected PFS, only performance status influenced overall survival (OS); patients receiving brent
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). In Phase 1, we characterized the safety and tolerability of Isa + Cemi with planned dose de-escalation to determine the recommended Phase 2 dose (RP2D).
View Article and Find Full Text PDFArticle Synopsis
- Doctors studied a new treatment called BV-AVD for patients with a tough type of cancer called early-stage unfavorable Hodgkin lymphoma.
- * The study involved 170 patients who either received BV-AVD or a standard treatment called ABVD and checked how many were cancer-free after two rounds of treatment.
- * The results showed that more patients treated with BV-AVD were cancer-free compared to those who had ABVD.
Purpose: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics.
Methods: Patients with relapsed/refractory MCL (one to five prior therapies, including prior BTKi exposure) received a single infusion of KTE-X19 (2 × 10 CAR T cells/kg).
Background: Intravascular large B-cell lymphoma (lVLBCL) is a very rare type of large B-cell lymphoma.
Methods: We conducted a retrospective study on IVLBCL patients treated from 2000 to 2016 in LYSA cooperative group centers.
Results: Sixty-five patients were identified in 23 centers.
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Bone Marrow Transplant
June 2022
Article Synopsis
- * The study found that patients receiving treatment at first relapse and those treated with specific chemotherapy combinations faced poorer prognoses and higher treatment-related mortality, especially when SCAT was administered beyond the first relapse.
- * Overall survival rates were significant, with 5-year survival at 80% for first-line treatment and 50% for first-relapse treatment, indicating the importance of timing in ASCT to improve the benefit/risk ratio for different chemotherapy regimens.